CG Oncology Future Growth
Future criteria checks 2/6
CG Oncology is forecast to grow earnings and revenue by 31.4% and 70.3% per annum respectively. EPS is expected to grow by 31.7% per annum. Return on equity is forecast to be -23% in 3 years.
Key information
31.4%
Earnings growth rate
31.7%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 70.3% |
| Future return on equity | -23.0% |
| Analyst coverage | Good |
| Last updated | 20 Nov 2024 |
Recent future growth updates
Recent updates
Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth
Oct 04
CG Oncology: Promising Data, But Looks Expensive
Aug 26CG Oncology, Inc. (NASDAQ:CGON) Shares Could Be 42% Below Their Intrinsic Value Estimate
Jul 25CG Oncology Bringing Undervalued Innovation To Bladder Cancer
Jul 09CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
May 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 107 | -89 | -121 | -21 | 6 |
| 12/31/2025 | 4 | -114 | -118 | -113 | 6 |
| 12/31/2024 | 1 | -78 | -94 | -88 | 6 |
| 9/30/2024 | 1 | -79 | -73 | -73 | N/A |
| 3/31/2024 | 1 | -72 | -64 | -64 | N/A |
| 12/31/2023 | 0 | -68 | -46 | -46 | N/A |
| 9/30/2023 | 0 | -57 | -38 | -38 | N/A |
| 12/31/2022 | 0 | -44 | -30 | -30 | N/A |
| 12/31/2021 | 10 | -18 | -14 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CGON is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CGON is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CGON is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CGON's revenue (70.3% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: CGON's revenue (70.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CGON is forecast to be unprofitable in 3 years.